- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03049579
Immune System Stimulation by Probiotic Food Supplementation
Immune System Stimulation by Probiotic Food Supplementation: a Double-blind, Randomized, Controlled, Parallel-designed, Prospective Trial
The purpose of this study is to investigate the effects of a probiotic supplementation on adult volunteers with having caught the common cold more than 4 times in the past year. This study is a single center, double-blind, randomized, controlled, parallel-designed, prospective trial. Subjects received a probiotic drink containing probiotics of Lactobacillus paracasei (108 colony forming units (CFU)/ml), Lactobacilluscasei431® (108CFU/ml) and Lactobacillus fermentiumPCC® (106CFU/ml) or an identical placebo without probiotics for a 12-week study period.
The incidence of flue and cold during the study period were compared between study groups.
Blood and fecal samples were collected at baseline and at the end of the intervention. Fecal samples were collected for the secretory immunoglobulin A (sIgA) analysis. Blood sample was drawn for interferon γ (IFN-γ), interleukin 4 (IL-4), interleukin 10 (IL-10), immunoglobulin A (IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM) analysis.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- male or female between 25 to 45 years old;
- having caught the common cold or flu at least 4 to 6 times in the past calendar year;
- signed the informed consent forms before entering the study;
- fully understood the risks and potential benefits in participating this study.
Exclusion Criteria:
- were diagnosed with the decreased immunity caused by any diagnosed chronic illness;
- having any gastrointestinal illness with medical treatment at the time of being enrolled;
- having any diagnosed respiratory illness with similar symptoms as the common cold and flu;
- currently taking any pain killer drug;
- having received any vaccine for the upper respiratory infection within 6 months before enrollment;
- having received any purgative drug or digestion related drug within 2 weeks before enrollment;
- having taken any dairy product containing prebiotics and probiotics within 10 days before enrollment;
- currently taking any preventive drug for upper respiratory infection;
- having received any drug which has impact with the immune system such as antibiotics within 3 months before enrollment;
- alcoholic or addicted to any drug;
- pregnant or breastfeeding mothers;
- having participated another clinical trial within 3 months before enrollment.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Weiquan Yogurt with probiotics
Weiquan Yogurt with probiotics contained Lactobacillus paracasei (108 colony forming units (CFU)/ml), Lactobacillus casei 431® (108 CFU/ml) and Lactobacillus fermentum PCC® (106 CFU/ml)
|
150 ml daily consumption for a total of 12 weeks
|
Placebo komparator: Weiquan Yogurt without probiotics
Weiquan Yogurt devoid of probiotics, but otherwise similar to the experimental product.
|
150 ml daily consumption for a total of 12 weeks
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Incidence of flue symptoms during the study
Tidsramme: end of week 12
|
Body temperature≥38.0℃,
and have one or more symptoms of cough, runny nose, throat pain, headache, muscle pain, weak feeling, hard to breath, chest pain or loss of appetite.
|
end of week 12
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Incidence of cold symptoms during the study
Tidsramme: end of week 12
|
Body temperature<38.0℃,
and have one or more symptoms of cough, runny nose, throat pain, headache, muscle pain, weak feeling, hard to breath, chest pain or loss of appetite.
|
end of week 12
|
Number of accumulated days of having cold symptoms during the study
Tidsramme: End of week 12
|
The total number of days of having one or more symptoms of cough, runny nose, throat pain, headache, muscle pain, weak feeling, hard to breath, chest pain or loss of appetite during the 12 week study period.
|
End of week 12
|
Serum IFN-γ concentration
Tidsramme: Baseline, end of week 12
|
Interferon gamma (unit: pg/ml)
|
Baseline, end of week 12
|
Serum IL-4 concentration
Tidsramme: Baseline, end of week 12
|
Interleukin 4 (unit: ng/ml)
|
Baseline, end of week 12
|
Serum IL-10 concentration
Tidsramme: Baseline, end of week 12
|
Interleukin 10 (unit: pg/ml)
|
Baseline, end of week 12
|
Serum IgA concentration
Tidsramme: Baseline, end of week 12
|
Immunoglobulin A (unit: g/L)
|
Baseline, end of week 12
|
Serum IgG concentration
Tidsramme: Baseline, end of week 12
|
Immunoglobulin G (unit: g/L)
|
Baseline, end of week 12
|
Serum IgM concentration
Tidsramme: Baseline, end of week 12
|
Immunoglobulin M (unit: g/L)
|
Baseline, end of week 12
|
Fecal sIgA concentration
Tidsramme: Baseline, end of week 12
|
Secretory Immunoglobulin A (unit: ng/ml)
|
Baseline, end of week 12
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 15-SC-09-WQ-002
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Influensa symptom
-
University Medical Center GroningenMartini Hospital GroningenFullført
-
Fundación SenefroBaxter Healthcare CorporationUkjentHemodialyse-indusert symptomSpania
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityHar ikke rekruttert ennåUreteral stent-relatert symptom
-
National Taiwan University HospitalFullførtHemodialysekomplikasjon | Hemodialyse-indusert symptomTaiwan
-
Queen's University, BelfastFullførtSymptom på inntrengingStorbritannia
-
Benha UniversityNew Jeddah Clinic HospitalFullførtHemodialyse-indusert symptom
-
Johns Hopkins UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... og andre samarbeidspartnereFullførtVold, innenriks | Voldsrelatert symptomForente stater
-
Instituto Nacional de Ciencias Medicas y Nutricion...FullførtOverholdelse av kjepphestdiett (symptom)
-
Mersin UniversityFullført
-
Sykehuset TelemarkFullførtEthvert symptom som krever koloskopiNorge